Comparative Pharmacology
Head-to-head clinical analysis: DRAXIMAGE DTPA versus RADIOGENIX SYSTEM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRAXIMAGE DTPA versus RADIOGENIX SYSTEM.
DRAXIMAGE DTPA vs RADIOGENIX SYSTEM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DRAXIMAGE DTPA (technetium Tc-99m pentetate) is a radiopharmaceutical that, after intravenous injection, distributes in the extracellular space and is cleared by glomerular filtration. It allows imaging of renal function and structure by emitting gamma radiation detectable by a gamma camera.
RADIOGENIX SYSTEM is a radiopharmaceutical that emits beta radiation (yttrium-90 microspheres) to deliver targeted radiotherapy to hepatic tumors via intra-arterial administration, causing irreversible DNA damage and cell death.
Diagnostic imaging: 3-5 mCi (111-185 MBq) IV for renal studies; 10-20 mCi (370-740 MBq) IV for lung perfusion imaging.
Not applicable; the RADIOGENIX SYSTEM is a medical imaging device, not a pharmacologic agent. No standard dosing.
None Documented
None Documented
Terminal elimination half-life is approximately 1.6 hours (range 1.2-2.0 hours) in patients with normal renal function; prolonged in renal impairment (up to 50 hours in severe cases).
Physical half-life of 6.0 hours for Tc-99m; effective half-life is approximately 6.0 hours due to rapid renal clearance.
Renal: 95% within 24 hours via glomerular filtration; biliary/fecal: <5%.
Primarily renal excretion; >95% of administered activity excreted in urine within 24 hours; negligible biliary or fecal elimination.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical